Development of a riboflavin and ultraviolet light-based device to treat whole blood

Transfusion

Volumn 53, Issue SUPPL. 1, 2013, Pages

  Reddy, Heather L ^a   Doane, Suzann K ^a   Keil, Shawn D ^a   Marschner, Susanne ^a   Goodrich, Raymond P ^a  

^a CaridianBCT Biotechnologies LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT; RIBOFLAVIN;

ARTICLE; BLEEDING; BLOOD; BLOOD SAFETY; BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; DISEASE TRANSMISSION; HUMAN; INFECTION; INSTRUMENTATION; LEUKOCYTE; METHODOLOGY; MILITARY MEDICINE; RADIATION EXPOSURE; RISK FACTOR; STANDARD; ULTRAVIOLET RADIATION;

BLOOD SAFETY; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; HEMORRHAGE; HUMANS; INFECTION; LEUKOCYTES; MILITARY MEDICINE; PHOTOSENSITIZING AGENTS; RIBOFLAVIN; RISK FACTORS; ULTRAVIOLET RAYS;

MLCS; MLOWN;

EID: 84874794455     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12047     Document Type: Article

References (24)

1. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white cell inactivation (MIRASOL PRT system). Transfus Med Rev 2008;22:133-53.
2. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50:2362-75.
3. Council of Europe. Guide to the preparation, use, and quality assurance of blood components. 16th ed. Strasbourg, France: European Directorate for the Quality of Medicines and Healthcare; 2010.
4. American Association of Blood Banks. Circular of information for the use of human blood and human blood components. Bethesda (MD): American Association of Blood Banks; 2009.
5. Fast LD, Nevola M, Tavares J, Reddy HL, Goodrich RP, Marschner S. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013. doi: 10.1111/j.1537-2995.2012. 03715.x.
6. Tonnetti L, Thorp AM, Reddy HL, Keil SD, Goodrich RP, Leiby DA. Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 2013. doi: 10.1111/j.1537-2995.2012.03791.x.
7. Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010;50:1019-27.
8. Erratum in: Transfusion 2010;50:1594.
9. Sullivan JJ, Bounngaseng A, Reddy H, Keil S, Goodrich R. Pathogen inactivation of plasmodium falciparum in plasma and platelet concentrates with riboflavin and UV light. 30th International Congress of the ISBT, Macao, SAR, China, June 7-12, 2008. Vox Sang 2008; 95(Suppl. 1):278.
10. Kiser P, Keil S, Marschner S, Avery A. Mirasol pathogen reduction technology (PRT) treatment of P. yoelii contaminated plasma neutralized parasite in a murine model for malaria. Vox Sang 2012;103(Suppl. 1):136.
11. Goodrich RP, Custer B, Keil S, Busch M. Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion 2010;50:1827-37.
12. Organización Panamericana de la Salud. Estimación cuantitativa de la enfermedad de Chagas en las Americas. Document OPS/HDM/CD/425-06. Montevideo, Uruguay: Organización Panamericana de la Salud; 2006.
13. Leiby DA, Herron RM Jr, Read EJ, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002;42:549-55.
14. Tonnetti L, Thorp AM, Reddy HL, Keil SD, Goodrich RP, Leiby DA. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012;52:409-16.
15. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011;38:8-18.
16. Goodrich RP, Doane S, Reddy HL. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010;38:20-30.
17. Keil S, Rapaport R, Young R, Cambell T, Marschner S. Viral reduction of intracellular HIV using the Mirasol system for whole blood. Vox Sang 2012;103(Suppl. 1):144.
18. Pidcoke HF, Delgado KK, Mora AG, Cap AP. Whole blood stored at four degrees retains platelet function, normal prothrombin time and overall hemostatic function as measured by thromboelastography. Transfusion 2011;51:SP8 (abstract).
19. Pidcoke HF, McFaul SJ, Ramasubramanian AK, Parida BK, Mora AG, Fedyk CG, Valdez-Delgado KK, Montgomery RK, Reddock KM, Rodriguez AC, Aden JK, Jones JA, Bryant RS, Scherer MR, Reddy HL, Goodrich RP, Cap AP. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time. Transfusion 2013;53(Suppl. 1):137S-49S.
20. Holme S, Moroff G, Murphy S. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer TransfusionWorking Party of the International Society of Blood Transfusion. Transfusion 1998;38: 31-40.
21. Cancelas JA, Rugg N, Fletcher D, Pratt PG, Worsham DN, Dunn SK, Marschner S, Reddy HL, Goodrich RP. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011;51:1460-8.
22. Doane SK, Wilkinson S, Hovenga N, Rouse L, Miklauz M, Reddy H, Marschner S, Goodrich R. Storage of packed red blood cells derived from whole blood treated with the Mirasol system. Vox Sang 2012;103(Suppl. 1):143.
23. Moroff G, Holme S, AuBuchon JP, Heaton W, Sweeney JD, Friedman LI. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 1999;39:128-129.
24. Wagner SJ, Myrup AC. Prestorage leucoreduction improves several in vitro red cell storage parameters following gamma irradiation. Transfus Med 2006;16:261-5.